GLP-TZ Tirzepatide 10mg | NeuroPept Labs

Description

Tirzepatide (GLP-TZ) is a synthetic 39-amino acid dual GIP and GLP-1 receptor agonist a novel molecular class termed “twincretin”engineered to activate both the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) through a single peptide backbone. This bispecific receptor engagement distinguishes Tirzepatide from monoagonist GLP-1 compounds and represents a significant advance in incretin-based metabolic research pharmacology.

NeuroPept Labs supplies Tirzepatide 10mg (GLP-TZ) as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are manufactured under controlled synthesis conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

Tirzepatide’s molecular design is based on the native GIP sequence, with modifications enabling GLP-1R co-agonism and incorporation of a C20 fatty diacid moiety for albumin binding and extended half-life (~5 days). Crucially, research demonstrates that Tirzepatide is a biased agonist at GLP-1R activating cAMP signalling preferentially over ÃŽ²-arrestin recruitment  a mechanistic property that differentiates it from native GLP-1 and other GLP-1R agonists at the receptor level.

• GIPR agonism  potentiates glucose-stimulated insulin secretion, augments post-meal insulin response, supports lipid metabolism in adipose tissue, and modulates bone metabolism signalling
• GLP-1R agonism (biased)  stimulates cAMP-mediated insulin secretion with preferential Gs-pathway engagement over ÃŽ²-arrestin; also suppresses glucagon, slows gastric emptying, and activates central satiety pathways
• Complementary receptor synergy  dual activation of GIPR and GLP-1R through a single molecule produces additive glycaemic and metabolic effects exceeding those of either monoagonist alone in preclinical and clinical studies
• Adipose tissue effects  GIPR is highly expressed in white adipose tissue; Tirzepatide’s GIPR agonism is studied for direct effects on fat cell lipid handling and adipokine signalling
• Extended half-life (~5 days) fatty acid conjugation enables albumin binding and once-weekly dosing in clinical research, relevant to longitudinal preclinical study design

Tirzepatide vs Semaglutide vs Retatrutide

NeuroPept Labs also supplies Retatrutide 10mg and Retatrutide 30mg for researchers studying the full spectrum of GLP-1/GIP/glucagon triple agonism.

Research Applications

• Incretin biology and dual receptor pharmacology  GIPR and GLP-1R co-activation studies, biased agonism characterisation at GLP-1R
• Type 2 diabetes research models beta-cell function, insulin secretion dynamics, and glycaemic regulation in cell-based and preclinical models
• Obesity and metabolic disease adipose tissue lipid metabolism, energy balance, and body weight regulation research
• Cardiovascular metabolic research cardiometabolic risk factor modulation and cardiac function in preclinical models
• NAFLD and hepatic steatosis liver fat reduction pathways in non-alcoholic fatty liver disease research models
• Comparative incretin pharmacology  side-by-side receptor activation studies comparing GLP-1 monoagonism vs GLP-1/GIP dual agonism vs GLP-1/GIP/glucagon triple agonism

Product Specifications

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended timeframes

Frequently Asked Questions

What is Tirzepatide (GLP-TZ)?

Tirzepatide (LY3298176, GLP-TZ) is a synthetic 39-amino acid dual GIP and GLP-1 receptor agonist a “twincretin” designed to simultaneously activate GIPR and GLP-1R through a single peptide molecule. It is studied in metabolic research for its effects on glucose homeostasis, insulin secretion, adipose tissue metabolism, and body weight regulation.

What makes Tirzepatide a “biased agonist” at GLP-1R?

Tirzepatide preferentially activates the Gs-cAMP signalling pathway at GLP-1R while having lower ÃŽ²-arrestin recruitment compared to native GLP-1 or semaglutide. This biased agonism is a pharmacologically distinct property under active research to understand whether it contributes to Tirzepatide’s differentiated metabolic effects in preclinical and clinical studies.

How does Tirzepatide compare to Retatrutide?

Tirzepatide is a dual GLP-1/GIP receptor agonist. Retatrutide adds a third receptor target the glucagon receptor (GCGR) introducing hepatic fat metabolism, lipolysis, and energy expenditure pathways not engaged by Tirzepatide. Both are available from NeuroPept Labs for comparative incretin pharmacology research.

What purity is NeuroPept Labs’ Tirzepatide 10mg?

Our Tirzepatide 10mg research peptide is supplied at â”°¥98% purity, verified by HPLC and third-party analytical testing. Full COA documentation is available for every batch and can be verified at freedomdiagnosticstesting.com.

Scientific References

1. Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist  PMC/NIH 2020
2. Unveiling Tirzepatide’s Therapeutic Spectrum: A Dual GIP/GLP-1 Review  PMC/NIH 2025
3. Insights into the Mechanism of Action of Tirzepatide PMC/NIH 2025

Research Use Disclaimer: All products sold by NeuroPept Labs are intended strictly for in vitro laboratory research and scientific investigation by qualified professionals. They are not approved for human consumption, medical treatment, or veterinary use. Purchasers are responsible for compliance with applicable regulations in their jurisdiction.